Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin plus bethanechol for dysuria in BPH patients with underactive bladder
KCT0005772Phase 4Terminated
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of terazosin, bethanechol in benign prostatic hyperplasia (BPH), Detrusor hypocontractility, sponsored by Il-Yang Pharmaceutical. Started Feb 2024; status: terminated.
02
Drugs
terazosinbethanechol
03
Conditions
benign prostatic hyperplasia (BPH)Detrusor hypocontractility
Beyond the preview
Go deeper on KCT0005772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005772.